not vested
UCrest in DNA test tie-up
27 Dec 2017
PETALING JAYA: Broadband, wireless and mobile health platform developer UCrest Bhd, formerly Palette Multimedia Bhd, has inked an agreement with US-based Pathway Genomics to provide personalised DNA tests.
These DNA tests come as part of the imedic Cloud Hospital ecosystem, offered through partnering hospitals, doctors and patients.
In a statement, UCrest founder and CEO Eg Kah Yee, said the test results would be integrated into the digital medical record for analysis, powered by the artificial intelligence capability of the imedic platform.
“Users can have access to the digital medical record using the app on smartphones at any time.
“These advanced and affordable tests will help millions of users to precisely identify disease-specific DNA markers and provide recommendations for preventive measures or treatment,” said Eg.
The DNA test can be easily done with a buccal swab to be collected at home or at the nearest participating clinics.
The samples will then be sent to the world-class Clinical Laboratory Improvement Amendments and College of American Pathologists-accredited clinical laboratory in the United States for processing.
Test results will be available in two to three weeks on the imedic mobile app or Pathway’s online physician/patient portal.
Pathway Genomics CEO Vadim Shulman said patients should not be deprived of latest advancements in genetics in other parts of the world.
“We will bridge this gap through collaboration efforts with United Crest Healthcare and cater to an estimated two billion people in the Asian region.
“The democratisation of genetic testing has already begun and we take pride in being at the forefront of this revolution,” said Shulman.
Pathway Genomics’ testing services cover a wide variety of conditions including hereditary cancer, cardiac health, carrier screening, diet and weight loss, as well as drug response for specific medications such as those used in pain management and mental health.
Families with the history of cancer, cardiovascular diseases, diabetes, obesity and hereditary diseases are generally encouraged to have the relevant DNA tests done for preventive purposes.
The DNA tests – such as Fit products, Fit IQ, Gluten Fit, skin products, mental health DNA insight, pain medication DNA insight, cardiac DNA insight, hereditary cancer tests, carrier status DNA insight and corporate wellness – will be available in Asean countries, Russia, China and Taiwan.
UCrest closed 3.6% higher at 43 sen, traded on a volume of 19.66 million shares.
For the first quarter to Aug 31, 2017, UCrest staged an impressive turnaround, recording a net profit of RM3.03mil on the back of RM7.84mil in revenue. This was from a previous loss of RM516,000 on the back of RM222,000 in revenue.
Since March this year, UCrest has been announcing a series of hardware platform sales to Trade House Atlantis Ltd.
UCrest continues to win more Russian hardware contracts up to December. To date, it has won more than RM40mil worth of contracts.
Source: The Star
https://www.thestar.com.my/business/bus ... YzszLPp.99